Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 2,601-2,625 of 3,186
CompletedNCT04822883

Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia

This study exists to better understand the safety of the medication RL-007 and how manageable it feels in practice. Researchers are trying to understand whether the medication RL-007 can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
Recognify Life Sciences
Condition
Schizophrenia
CompletedNCT05106309

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

This study exists to explore whether the medication CVL-231 could improve care and understanding. Researchers are trying to understand what the medication CVL-231 could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Cerevel Therapeutics, LLC
Condition
Schizophrenia
CompletedNCT04510298

A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia

This study exists to compare options and see whether the medication SP-624 offers something meaningfully different. Researchers are trying to understand how people respond to the medication SP-624 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Sirtsei Pharmaceuticals, Inc.
Condition
Schizophrenia
CompletedNCT03969589

Reproductive Life Planning for Women With Mental Illness

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United States
Sponsor
VA Office of Research and Development
Condition
Schizophrenia
CompletedNCT02069925

STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what helps a digital app or remote support tool stay useful, realistic, and easier to follow over time.

SchizophreniaOtherFrom 16 Years to 35 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
TerminatedNCT03593213

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand whether a medication treatment can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
Bulgaria, Malaysia, Poland, United States, Romania, Serbia, South Korea, Taiwan, Thailand, Ukraine
Sponsor
AbbVie
Condition
Schizophrenia
CompletedNCT01451736

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

This study exists to compare options and see whether a guided support group offers something meaningfully different. Researchers are trying to understand whether a guided support group can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United States
Sponsor
University of California, Los Angeles
Condition
Schizophrenia
CompletedNCT03870880

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Ukraine, United States
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia
CompletedNCT00161044

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
WithdrawnNCT01584466

Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can work better when mental health difficulties overlap with substance use.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT00176436

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

This study exists to explore whether a guided support group could improve care and understanding. Researchers are trying to understand what a guided support group could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT01182727

Salsalate for Insulin Resistance in Schizophrenia

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT00708994

Cannabinoids, Neural Synchrony, and Information Processing

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
CompletedNCT01514682

Anti-Inflammatory Treatment of Schizophrenia

This study exists to see whether a therapy or guided support program can play a useful role in care. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
TerminatedNCT03868839

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

This study exists to see whether blood tests and biological markers is workable and worth testing more broadly. Researchers are trying to understand what blood tests and biological markers can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Xiaoduo Fan
Condition
Schizophrenia
CompletedNCT03160521

Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Ukraine, United States
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia
CompletedNCT00295139

Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can work better when mental health difficulties overlap with substance use.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT03221270

Targeting Auditory Hallucinations With Alternating Current Stimulation

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 70 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia
WithdrawnNCT04054973

L-arginine Study for Persistent Symptoms of Schizophrenia

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Massachusetts, Worcester
Condition
Schizophrenia
CompletedNCT02417142

Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia

This study exists to compare options and see whether a therapy or guided support program offers something meaningfully different. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Massachusetts, Worcester
Condition
Schizophrenia
CompletedNCT01012167

Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand whether this type of care can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT02968602

Minocycline and Tobacco Craving in Smokers With Schizophrenia

This study exists to see whether smoking support or smoking-related treatment is workable and worth testing more broadly. Researchers are trying to understand whether smoking support or smoking-related treatment can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT02118610

Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT00492349

Varenicline Adjunctive Treatment in Schizophrenia

This study exists to explore whether smoking support or smoking-related treatment could improve care and understanding. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT05179525

Comparative Bioavailability of Risperidone.

This study exists to explore whether a digital app or remote support tool could improve care and understanding. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia